Overcoming FVIII Inhibitors With Efanesoctocog Alfa – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Aqsa Ashraf et. al, adding:
“Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series
Two patients with severe hemophilia A and complex inhibitor histories underwent immune tolerance induction with efanesoctocog alfa at 100 U/kg three times weekly.
Inhibitor titers became undetectable within six weeks and three months, with FVIII recovery above 90%.
Once-weekly prophylaxis maintained troughs of 4-6% and bleed-free outcomes, allowing emicizumab discontinuation.”
Title: Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series
Authors: Aqsa Ashraf, Rebekah Kuhlman, Osman Khan, Sanober Nusrat

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series